GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » Cyclically Adjusted Book per Share

PMCB (PharmaCyte Biotech) Cyclically Adjusted Book per Share : $9.21 (As of Jan. 2025)


View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

PharmaCyte Biotech's adjusted book value per share for the three months ended in Jan. 2025 was $5.829. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $9.21 for the trailing ten years ended in Jan. 2025.

During the past 12 months, PharmaCyte Biotech's average Cyclically Adjusted Book Growth Rate was -12.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 15.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 21.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of PharmaCyte Biotech was 34.30% per year. The lowest was -30.40% per year. And the median was 14.00% per year.

As of today (2025-05-18), PharmaCyte Biotech's current stock price is $1.06. PharmaCyte Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2025 was $9.21. PharmaCyte Biotech's Cyclically Adjusted PB Ratio of today is 0.12.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of PharmaCyte Biotech was 0.12. The lowest was 0.00. And the median was 0.00.


PharmaCyte Biotech Cyclically Adjusted Book per Share Historical Data

The historical data trend for PharmaCyte Biotech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCyte Biotech Cyclically Adjusted Book per Share Chart

PharmaCyte Biotech Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.49 6.63 8.99 10.87 10.08

PharmaCyte Biotech Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.46 10.08 9.73 9.46 9.21

Competitive Comparison of PharmaCyte Biotech's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, PharmaCyte Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCyte Biotech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Cyclically Adjusted PB Ratio falls into.


;
;

PharmaCyte Biotech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PharmaCyte Biotech's adjusted Book Value per Share data for the three months ended in Jan. 2025 was:

Adj_Book= Book Value per Share /CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=5.829/134.0288*134.0288
=5.829

Current CPI (Jan. 2025) = 134.0288.

PharmaCyte Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201504 15.904 99.824 21.354
201507 14.055 100.691 18.709
201510 13.150 100.346 17.564
201601 13.494 99.957 18.094
201604 12.520 100.947 16.623
201607 12.486 101.524 16.484
201610 11.101 101.988 14.589
201701 12.091 102.456 15.817
201704 13.389 103.167 17.394
201707 13.342 103.278 17.315
201710 11.322 104.070 14.581
201801 8.927 104.578 11.441
201804 8.534 105.708 10.820
201807 8.608 106.324 10.851
201810 7.495 106.695 9.415
201901 7.136 106.200 9.006
201904 6.372 107.818 7.921
201907 5.958 108.250 7.377
201910 5.106 108.577 6.303
202001 4.532 108.841 5.581
202004 4.656 108.173 5.769
202007 4.992 109.318 6.120
202010 5.316 109.861 6.485
202101 4.874 110.364 5.919
202104 4.201 112.673 4.997
202107 3.543 115.183 4.123
202110 4.447 116.696 5.108
202201 4.408 118.619 4.981
202204 4.340 121.978 4.769
202207 4.159 125.002 4.459
202210 4.150 125.734 4.424
202301 4.235 126.223 4.497
202304 4.328 127.992 4.532
202307 4.868 128.974 5.059
202310 4.226 129.810 4.363
202401 3.682 130.124 3.792
202404 3.440 132.289 3.485
202407 6.182 132.708 6.244
202410 6.177 133.182 6.216
202501 5.829 134.029 5.829

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


PharmaCyte Biotech  (NAS:PMCB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

PharmaCyte Biotech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.06/9.21
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of PharmaCyte Biotech was 0.12. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


PharmaCyte Biotech Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaCyte Biotech Business Description

Industry
Traded in Other Exchanges
N/A
Address
3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb director 100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen director 299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K director
Carlos Trujillo director, officer: CFO 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner director, officer: Chairman, CEO, Pres and GC 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree director, officer: Chief Science Officer 12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099